Prostate News and Research

RSS

IsoRay announces presentation video on metastatic brain cancers by Cornell Weill

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds.

6 Feb 2013

CIHR-funded researchers raise awareness of sexual health

Being comfortable in our sexuality and making choices that support our sexual health are essential to our overall well-being. Promoting sexual health includes both preventing disease and helping people find pleasure in their sexual lives.

6 Feb 2013

Previously poorly investigated signalling pathway crucial for proliferation of prostate cancer cells

A previously poorly investigated signalling pathway is crucial for the growth and proliferation of prostate cancer cells. An international research team discovered this when studying the enzyme "soluble adenylyl cyclase" that produces the second messenger molecule cAMP.

5 Feb 2013

Delayed hematuria common after prostate brachytherapy

A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers.

4 Feb 2013

Cutting down on fried food could lower prostate cancer risk

Men who eat deep-fried food at least once a week may be increasing their risk for developing prostate cancer, show findings from a US study.

4 Feb 2013

VMAT use to deliver prostate intensity-modulated radiation therapy reduces treatment time

According to a study in the January issue of the Journal of the American College of Radiology, the use of volume-modulated arc therapy (VMAT) to deliver intensity-modulated radiation therapy (IMRT) to prostate cancer patients results in an overall reduction in treatment time of approximately 14 percent. The study was performed at Winship Cancer Institute of Emory University in Atlanta.

3 Feb 2013

Obesity becoming serious problem, comparable to cigarette smoking

Dr. Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published a report in the current issue of the American Journal of Medicine that obesity is becoming as big a hazard worldwide, comparable to cigarette smoking.

1 Feb 2013

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

Study finds serious long-term side effects following prostate cancer treatments

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment.

31 Jan 2013

Pelvic floor exercises after RP ‘sufficient’

Performing pelvic floor muscle training both before and after radical prostatectomy is no more effective at reducing postoperative urinary incontinence than performing the exercises after surgery, report researchers.

30 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

Regular deep-fried food consumption may increase risk of prostate cancer

Regular consumption of deep-fried foods such as French fries, fried chicken and doughnuts is associated with an increased risk of prostate cancer, and the effect appears to be slightly stronger with regard to more aggressive forms of the disease, according to a study by investigators at Fred Hutchinson Cancer Research Center.

29 Jan 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

Emotional stress can reduce prostate cancer drugs’ effectiveness

Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study by researchers at Wake Forest Baptist Medical Center indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer.

29 Jan 2013

Cancer risk independent of folic acid supplementation

Folic acid supplementation does not increase or decrease the risk for cancer, suggests research published in The Lancet.

28 Jan 2013

Urinary incontinence risk tool helps guide radical prostatectomy patients

Researchers have developed a multivariable risk classification tool for estimating patients’ risk for urinary incontinence after undergoing radical prostatectomy for prostate cancer.

28 Jan 2013

Prediagnostic androgen level not linked to prostate cancer outcome

Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Behavioral stress accelerates prostate cancer development in mice

Prostate cancer patients have increased levels of stress and anxiety; however, several recent studies have found that men who take drugs that interfere with the stress hormone adrenaline have a lower incidence of prostate cancer.

28 Jan 2013